ClinicalTrials.gg
CompletedNCT01146574Updated Mar 1, 2024Results posted

A Phase 2a Study To Evaluate The Pharmacokinetics, Safety, Efficacy, Tolerability, And Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease on Hemodialysis.

A Phase 2 interventional study of Sotatercept and Placebo in Anemia, sponsored by Celgene. Completed at 24 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-01.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Anemia by Bristol-Myers Squibb — 1 open to participants now, 8 under way, 5 of them phase 3. Anemia · Bristol-Myers Squibb.

Enrollment
12th of 15
50 · median 189
Started
2010
with 1 other
Phase 2
6 of 16
none open now
Registered
3rd of 16
by date

Among the 16 studies in Anemia by Bristol-Myers Squibb, this one is the 12th largest by enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2010, is one of 6 in phase 2, and was the 3rd registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

1 of the 16 studies in Anemia by Bristol-Myers Squibb is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Anemia by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

This is the first study in hemodialysis subjects with anemia to evaluate the pharmacokinetics, safety, efficacy, tolerability, and pharmacodynamics of sotatercept (ACE-011)

Read the detailed description

Part 1:

Approximately 8 subjects will be randomized to receive either a single 0.1 mg/kg subcutaneous dose of sotatercept or matching placebo in a 3:1 ratio

Part 2:

Approximately 8 subjects will be randomized to each of the 3 sequential dose groups (0.3mg/kg or 0.5mg/kg or 0.7 mg/kg) with a 3:1 ratio of sotatercept or placebo (6 subjects in the sotatercept arm and 2 in the placebo arm). A total of 24-36 subjects may be randomized in the 3 dose groups.

03

Conditions studied

  • Anemia

Keywords

  • End-Stage Renal Disease
  • Anemia
  • Hemodialysis
  • Renal Anemia
  • ESRD
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or females ≥18 years of age.
  • Subjects on hemodialysis for at least 12 weeks before screening
  • Subjects on a stable dose of Erythrocyte Stimulating Agents product to maintain (Hb) for at least 6 weeks prior to screening.
  • 3 consecutive pre-dialysis Hb concentrations with a mean ≥10 to ≤ 12 g/dL (≥100 to ≤120 g/L) at screening and one pre-dialysis Hb concentration ≥8 to \< 10 g/dL (≥ 80 to \< 100 g/L) before randomization.
  • Adequate iron status defined as serum transferrin saturation ≥ 20% before randomization.

Exclusion criteria

Exclusion Criteria:

  • Non renal causes of anemia.
  • Subjects on peritoneal dialysis.
  • Systemic hematological disease
  • High sensitivity C-reactive protein >50mg/L at screening.
  • (ALT) or aspartate transaminase (AST) laboratory values > 2 times the (ULN) at screening.
  • Uncontrolled diabetes mellitus ( > 9) at screening.
  • Uncontrolled hypertension.
  • Red Blood Count (RBC) transfusions within 8 weeks prior to screening.
  • Active serious infection or history of recurrent serious infection likely to recur during the study
  • History of severe allergic or anaphylactic reactions or to recombinant proteins or in the product or to the iron products needed to normalize iron levels for subjects.
  • Subjects that received treatment with another investigational drug or device within 28 days prior to Day 1
  • Pregnant or lactating females.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Single (Participant)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    0.1mg/kg Sotatercept

    Approximately 8 subjects will be randomized to receive either a single 0.1 mg/kg subcutaneous dose of sotatercept or matching placebo in a 3:1 ratio

    Biological: Sotatercept

  • Experimental
    0.3mg/kg Sotatercept

    Dose Group 1: 0.3 mg/kg sotatercept subcutaneous every 28 days

    Biological: Sotatercept

  • Experimental
    0.5mg/kg Sotatercept

    Dose Group 2: 0.5 mg/kg sotatercept subcutaneous every 28 days

    Biological: Sotatercept

  • Experimental
    0.7mg/kg Sotatercept

    Dose Group 3: 0.7 mg/kg sotatercept subcutaneous every 28 days

    Biological: Sotatercept

  • Placebo comparator
    Placebo

    The Placebo to Sotatercept ratio is 1:3 meaning for every 1 patient that receives Placebo, 3 patients will receive Sotatercept.

    Biological: Placebo

Interventions

  • BiologicalSotatercept

    Part 1: Sotatercept single dose 0.1mg/kg subcutaneous Part 2: Sotatercept starting dose groups of 0.3mg/kg, 0.5mg/kg or 0.7 mg/kg in a sequential design, dosed subcutaneously every 28 days for up to 8 doses

    Also known as: ACE-011

  • BiologicalPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Observed Maximum Concentration (Cmax)

    Cmax is a pharmacokinetic parameter defined as the observed maximum concentration of the study drug in the serum and/or blood. Cmax will be estimated from the sotatercept concentration versus time data using noncompartmental method.

    Time frame: From first dose up to Day 28

  2. Time to Maximum Concentration (Tmax)

    Time to observed maximum concentration (Tmax) is defined as the amount of time in days for a drug to reach the maximum concentration after administration.

    Time frame: From first dose up to Day 28

  3. Area Under Curve (AUC)-28 Days

    AUC-28 days is defined as area under the concentration-time curve over the first 28-day dosing interval

    Time frame: From first dose up to Day 28

  4. AUCinf: Area Under the Concentration-time Curve From Time Zero Extrapolated to Infinity

    Area under the concentration-time curve from time zero extrapolated to infinity. Only Part 1 pharmacokinetic evaluable participants were pre-specified to be evaluated in this endpoint.

    Time frame: From first dose up to Day 28

  5. Apparent Total Clearance (CL/F)

    Apparent Total Clearance (CL/F) is defined as the volume of plasma from which the study drug is completely removed per unit of time. It is equal to the drug dose divided by the area-under-the-curve.

    Time frame: From first dose up to Day 28

  6. Apparent Volume of Distribution Based on Terminal Phase (Vz/F)

    Apparent volume of distribution based on terminal phase (Vz/F) is defined as the apparent volume in which the current amount of drug in the body must be dispersed in order to give the current plasma concentration. Apparent volume of distribution is important for determining the dose required to produce a desired plasma concentration of the drug.

    Time frame: From first dose up to Day 28

  7. Terminal Half-Life (t1/2,z)

    Terminal plasma half-life (t1/2,z) is the time taken for concentration of the study drug to decrease from its maximum concentration (Cmax) to half of Cmax in the blood plasma.

    Time frame: Days 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 15, 22, 29, 43, 57, 85 and 113

Secondary outcomes

  1. The Number of Participants Experiencing Treatment Emergent Adverse Events (TEAEs)

    An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.

    Time frame: From first dose up to 115 days post last dose

  2. Number of Participants With Hemoglobin > 12g/dL

    Number of participants with hemoglobin \> 12g/dL including Hb values obtained after first study drug dose and before any rescue.

    Time frame: Pre-dose; Dose 1-Days 1, 8, 15, 22, 29; Doses 2, 3, 4, 5, 6, 7-Days 1, 15, 29; Follow-up Phase Days 225, 253, 281, and 309

  3. Proportion of Participants With Rise in Hemoglobin > 2 g/dL During 4 Week Period

    Proportion of participants with rise in hemoglobin (Hb) \> 2 g/dL during a 4-week period including Hb values obtained after first study drug dose and before any rescue.

    Time frame: Pre-dose; Dose 1-Days 1, 8, 15, 22, 29; Doses 2, 3, 4, 5, 6, 7-Days 1, 15, 29; Follow-up Phase Days 225, 253, 281, and 309

  4. Blood Pressure Changes From Baseline

    Blood pressure was generally recorded on the day of dialysis and represent pre-dialysis values. Baseline is defined as blood pressure measurements recorded on Day 1 of the first dose administered.

    Time frame: From pre-dose up to the final visit 112 days after last dose (up to 225 days)

  5. Changes in Follicle Stimulating Hormone (FSH)

    The change in follicle stimulating measured at pre-specified timepoints throughout the treatment period.

    Time frame: Day 1 (baseline), Day 15, Day 29, and Day 113

  6. Number of Participants With Hemoglobin > 10g/dL

    Number of participants with hemoglobin \> 10g/dL including Hb values obtained after first study drug dose and before any rescue. Baseline is defined as hemoglobin measurements recorded on Day 1 of the first dose administered.

    Time frame: Pre-dose; Dose 1-Days 1, 8, 15, 22, 29; Doses 2, 3, 4, 5, 6, 7-Days 1, 15, 29; Follow-up Phase Days 225, 253, 281, and 309

  7. Number of Participants With Change From Baseline Hemoglobin ≥ 1g/dL

    Number of participants with a change from in hemoglobin values ≥ 1g/dL including Hb values obtained after first study drug dose and before any rescue. Baseline is defined as hemoglobin measurements recorded on Day 1 of the first dose administered.

    Time frame: Pre-dose; Dose 1-Days 1, 8, 15, 22, 29; Doses 2, 3, 4, 5, 6, 7-Days 1, 15, 29; Follow-up Phase Days 225, 253, 281, and 309

  8. Number of Participants With Hemoglobin > 10g/dL and Change From Baseline Hemoglobin ≥ 1g/dL

    Number of participants with Hemoglobin \> 10g/dL and a change from in hemoglobin values ≥ 1g/dL including Hb values obtained after first study drug dose and before any rescue. Baseline is defined as hemoglobin measurements recorded on Day 1 of the first dose administered.

    Time frame: Pre-dose; Dose 1-Days 1, 8, 15, 22, 29; Doses 2, 3, 4, 5, 6, 7-Days 1, 15, 29; Follow-up Phase Days 225, 253, 281, and 309

  9. Length of Time to Rescue Therapy

    The length of time in days that participants who were rescued received treatment. When applicable, participants were rescued for anemia. During the rescue, participants discontinued sotatercept and were unblinded to the study treatment. Participants who were rescued continued in the treatment phase of 200 days and a follow-up phase of 112 days after the treatment phase. Rescue is defined as the need for a blood transfusion or Erythropoiesis-stimulating agent (ESA) therapy.

    Time frame: From first dose up to blood transfusion or ESA therapy, up to approximately 209 days

  10. Change From Baseline in Hemoglobin Values

    Dose Cycle 1 is defined as the first 28 days of treatment for Dose Groups 0.3 mg/kg, 0.5 mg/kg, and 0.7 mg/kg and the first 14 days of treatment for Dose Group 0.7/0.4 mg/kg. End of the Treatment Period is defined as the day before the follow-up phase started. Baseline is defined as hemoglobin measurements recorded on Day 1 of the first dose administered.

    Time frame: From first dose up to Day 225

07

Results

Posted Mar 1, 2024

Participant flow

Participant flow — Overall Study
MilestonePart 1-PlaceboPart 1-ACE-011 0.1 mg/kgPart 2- PlaceboPart 2-0.3 mg/kgPart 2-0.5 mg/kgPart 2-0.7 mg/kgPart 2-0.7/0.4 mg/kg
Started16119896
Completed1557685
Not completed0162211
Withdrew: Death0110000
Withdrew: Other reasons0030000
Withdrew: Kidney transplant0011000
Withdrew: Withdrew consent0011211

Outcome measures

PrimaryObserved Maximum Concentration (Cmax)

Cmax is a pharmacokinetic parameter defined as the observed maximum concentration of the study drug in the serum and/or blood. Cmax will be estimated from the sotatercept concentration versus time data using noncompartmental method.

Time frame:
From first dose up to Day 28
Reported as:
Mean · ug/mL
Observed Maximum Concentration (Cmax)
ug/mLPart 1-PlaceboPart 1-ACE-011 0.1 mg/kgPart 2- PlaceboPart 2-0.3 mg/kgPart 2-0.5 mg/kgPart 2-0.7 mg/kgPart 2-0.7/0.4 mg/kg
Observed Maximum Concentration (Cmax)—1.022 ± 0.576—2.40 ± 0.963.66 ± 0.673.97 ± 1.647.71 ± 1.97
PrimaryTime to Maximum Concentration (Tmax)

Time to observed maximum concentration (Tmax) is defined as the amount of time in days for a drug to reach the maximum concentration after administration.

Time frame:
From first dose up to Day 28
Reported as:
Median · Days
Time to Maximum Concentration (Tmax)
DaysPart 1-PlaceboPart 1-ACE-011 0.1 mg/kgPart 2- PlaceboPart 2-0.3 mg/kgPart 2-0.5 mg/kgPart 2-0.7 mg/kgPart 2-0.7/0.4 mg/kg
Time to Maximum Concentration (Tmax)—6 (3 to 14)—7 (3 to 14)8 (4 to 12)7 (4 to 10)5 (3 to 13)
PrimaryArea Under Curve (AUC)-28 Days

AUC-28 days is defined as area under the concentration-time curve over the first 28-day dosing interval

Time frame:
From first dose up to Day 28
Reported as:
Mean · ug·day/mL
Area Under Curve (AUC)-28 Days
ug·day/mLPart 1-PlaceboPart 1-ACE-011 0.1 mg/kgPart 2- PlaceboPart 2-0.3 mg/kgPart 2-0.5 mg/kgPart 2-0.7 mg/kgPart 2-0.7/0.4 mg/kg
Area Under Curve (AUC)-28 Days—20.6 ± 11.4—50.64 ± 17.6778.03 ± 13.3487.51 ± 36.68126.96 ± 20.75
PrimaryAUCinf: Area Under the Concentration-time Curve From Time Zero Extrapolated to Infinity

Area under the concentration-time curve from time zero extrapolated to infinity. Only Part 1 pharmacokinetic evaluable participants were pre-specified to be evaluated in this endpoint.

Time frame:
From first dose up to Day 28
Reported as:
Mean · ug·day/mL
AUCinf: Area Under the Concentration-time Curve From Time Zero Extrapolated to Infinity
ug·day/mLPart 1-PlaceboPart 1-ACE-011 0.1 mg/kgPart 2- PlaceboPart 2-0.3 mg/kgPart 2-0.5 mg/kgPart 2-0.7 mg/kgPart 2-0.7/0.4 mg/kg
AUCinf: Area Under the Concentration-time Curve From Time Zero Extrapolated to Infinity—35.8 ± 17.4—————
PrimaryApparent Total Clearance (CL/F)

Apparent Total Clearance (CL/F) is defined as the volume of plasma from which the study drug is completely removed per unit of time. It is equal to the drug dose divided by the area-under-the-curve.

Time frame:
From first dose up to Day 28
Reported as:
Mean · L/day
Apparent Total Clearance (CL/F)
L/dayPart 1-PlaceboPart 1-ACE-011 0.1 mg/kgPart 2-PlaceboPart 2-0.3 mg/kgPart 2-0.5 mg/kgPart 2-0.7 mg/kgPart 2-0.7/0.4 mg/kg
Apparent Total Clearance (CL/F)—3.22 ± 1.20—0.255 ± 0.0680.261 ± 0.0750.532 ± 0.6540.298 ± 0.112
PrimaryApparent Volume of Distribution Based on Terminal Phase (Vz/F)

Apparent volume of distribution based on terminal phase (Vz/F) is defined as the apparent volume in which the current amount of drug in the body must be dispersed in order to give the current plasma concentration. Apparent volume of distribution is important for determining the dose required to produce a desired plasma concentration of the drug.

Time frame:
From first dose up to Day 28
Reported as:
Mean · mL/kg
Apparent Volume of Distribution Based on Terminal Phase (Vz/F)
mL/kgPart 1-PlaceboPart 1-ACE-011 0.1 mg/kgPart 2- PlaceboPart 2-0.3 mg/kgPart 2-0.5 mg/kgPart 2-0.7 mg/kgPart 2-0.7/0.4 mg/kg
Apparent Volume of Distribution Based on Terminal Phase (Vz/F)—98 ± 38—————
PrimaryTerminal Half-Life (t1/2,z)

Terminal plasma half-life (t1/2,z) is the time taken for concentration of the study drug to decrease from its maximum concentration (Cmax) to half of Cmax in the blood plasma.

Time frame:
Days 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 15, 22, 29, 43, 57, 85 and 113
Reported as:
Mean · Day
Terminal Half-Life (t1/2,z)
DayPart 1-PlaceboPart 1-ACE-011 0.1 mg/kgPart 2- PlaceboPart 2-0.3 mg/kgPart 2-0.5 mg/kgPart 2-0.7 mg/kgPart 2-0.7/0.4 mg/kg
Terminal Half-Life (t1/2,z)—21.1 ± 3.9—24.3 ± 3.2832.1 ± 19.922.2 ± 7.0019.6 ± 2.91
SecondaryThe Number of Participants Experiencing Treatment Emergent Adverse Events (TEAEs)

An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment.

Time frame:
From first dose up to 115 days post last dose
Reported as:
Count of participants · Participants
The Number of Participants Experiencing Treatment Emergent Adverse Events (TEAEs)
ParticipantsPart 1-PlaceboPart 1-ACE-011 0.1 mg/kgPart 2- PlaceboPart 2-0.3 mg/kgPart 2-0.5 mg/kgPart 2-0.7 mg/kgPart 2-0.7/0.4 mg/kg
The Number of Participants Experiencing Treatment Emergent Adverse Events (TEAEs)1678684
SecondaryNumber of Participants With Hemoglobin > 12g/dL

Number of participants with hemoglobin \> 12g/dL including Hb values obtained after first study drug dose and before any rescue.

Time frame:
Pre-dose; Dose 1-Days 1, 8, 15, 22, 29; Doses 2, 3, 4, 5, 6, 7-Days 1, 15, 29; Follow-up Phase Days 225, 253, 281, and 309
Reported as:
Count of participants · Participants
Number of Participants With Hemoglobin > 12g/dL
ParticipantsPart 1-PlaceboPart 1-ACE-011 0.1 mg/kgPart 2- PlaceboPart 2-0.3 mg/kgPart 2-0.5 mg/kgPart 2-0.7 mg/kgPart 2-0.7/0.4 mg/kg
Number of Participants With Hemoglobin > 12g/dL0000010
SecondaryProportion of Participants With Rise in Hemoglobin > 2 g/dL During 4 Week Period

Proportion of participants with rise in hemoglobin (Hb) \> 2 g/dL during a 4-week period including Hb values obtained after first study drug dose and before any rescue.

Time frame:
Pre-dose; Dose 1-Days 1, 8, 15, 22, 29; Doses 2, 3, 4, 5, 6, 7-Days 1, 15, 29; Follow-up Phase Days 225, 253, 281, and 309
Reported as:
Count of participants · Participants
Proportion of Participants With Rise in Hemoglobin > 2 g/dL During 4 Week Period
ParticipantsPart 1-PlaceboPart 1-ACE-011 0.1 mg/kgPart 2- PlaceboPart 2-0.3 mg/kgPart 2-0.5 mg/kgPart 2-0.7 mg/kgPart 2-0.7/0.4 mg/kg
Proportion of Participants With Rise in Hemoglobin > 2 g/dL During 4 Week Period0000100
SecondaryBlood Pressure Changes From Baseline

Blood pressure was generally recorded on the day of dialysis and represent pre-dialysis values. Baseline is defined as blood pressure measurements recorded on Day 1 of the first dose administered.

Time frame:
From pre-dose up to the final visit 112 days after last dose (up to 225 days)
Reported as:
Mean · mmHg
Blood Pressure Changes From Baseline
mmHgPart 1-PlaceboPart 1-ACE-011 0.1 mg/kgPart 2- PlaceboPart 2-0.3 mg/kgPart 2-0.5 mg/kgPart 2-0.7 mg/kgPart 2-0.7/0.4 mg/kg
Systolic Blood Pressure Baseline Day 1151.0 ± NA142.8 ± 13.11129.4 ± 27.99145.9 ± 9.75141.4 ± 18.72139.9 ± 29.25135.0 ± 25.09
Systolic Blood Pressure Final Visit163.0 ± NA134.6 ± 6.95145.0 ± 26.91167.0 ± 12.81154.0 ± 34.47154.3 ± 22.93131.8 ± 12.79
Diastolic Blood Pressure Baseline Day 175.0 ± NA81.5 ± 7.5671.6 ± 13.4278.2 ± 12.4574.3 ± 8.4164.6 ± 13.3372.0 ± 16.10
Diastolic Blood Pressure Final Visit83.0 ± NA86.2 ± 15.9379.7 ± 15.5385.2 ± 9.8383.6 ± 18.9875.3 ± 9.1971.6 ± 10.01
SecondaryChanges in Follicle Stimulating Hormone (FSH)

The change in follicle stimulating measured at pre-specified timepoints throughout the treatment period.

Time frame:
Day 1 (baseline), Day 15, Day 29, and Day 113
Reported as:
Mean · IU/L
Changes in Follicle Stimulating Hormone (FSH)
IU/LPart 1-PlaceboPart 1-ACE-011 0.1 mg/kg
Day 1 (baseline)23.5 ± NA36.9 ± 67.65
Day 1517.1 ± NA51.8 ± 80.76
Day 2917.5 ± NA37.4 ± 67.69
Day 11311.8 ± NA48.2 ± 78.81
SecondaryNumber of Participants With Hemoglobin > 10g/dL

Number of participants with hemoglobin \> 10g/dL including Hb values obtained after first study drug dose and before any rescue. Baseline is defined as hemoglobin measurements recorded on Day 1 of the first dose administered.

Time frame:
Pre-dose; Dose 1-Days 1, 8, 15, 22, 29; Doses 2, 3, 4, 5, 6, 7-Days 1, 15, 29; Follow-up Phase Days 225, 253, 281, and 309
Reported as:
Count of participants · Participants
Number of Participants With Hemoglobin > 10g/dL
ParticipantsPart 2- PlaceboPart 2-0.3 mg/kgPart 2-0.5 mg/kgPart 2-0.7 mg/kgPart 2-0.7/0.4 mg/kg
Number of Participants With Hemoglobin > 10g/dL33572
SecondaryNumber of Participants With Change From Baseline Hemoglobin ≥ 1g/dL

Number of participants with a change from in hemoglobin values ≥ 1g/dL including Hb values obtained after first study drug dose and before any rescue. Baseline is defined as hemoglobin measurements recorded on Day 1 of the first dose administered.

Time frame:
Pre-dose; Dose 1-Days 1, 8, 15, 22, 29; Doses 2, 3, 4, 5, 6, 7-Days 1, 15, 29; Follow-up Phase Days 225, 253, 281, and 309
Reported as:
Count of participants · Participants
Number of Participants With Change From Baseline Hemoglobin ≥ 1g/dL
ParticipantsPart 2- PlaceboPart 2-0.3 mg/kgPart 2-0.5 mg/kgPart 2-0.7 mg/kgPart 2-0.7/0.4 mg/kg
Number of Participants With Change From Baseline Hemoglobin ≥ 1g/dL23472
SecondaryNumber of Participants With Hemoglobin > 10g/dL and Change From Baseline Hemoglobin ≥ 1g/dL

Number of participants with Hemoglobin \> 10g/dL and a change from in hemoglobin values ≥ 1g/dL including Hb values obtained after first study drug dose and before any rescue. Baseline is defined as hemoglobin measurements recorded on Day 1 of the first dose administered.

Time frame:
Pre-dose; Dose 1-Days 1, 8, 15, 22, 29; Doses 2, 3, 4, 5, 6, 7-Days 1, 15, 29; Follow-up Phase Days 225, 253, 281, and 309
Reported as:
Count of participants · Participants
Number of Participants With Hemoglobin > 10g/dL and Change From Baseline Hemoglobin ≥ 1g/dL
ParticipantsPart 2- PlaceboPart 2-0.3 mg/kgPart 2-0.5 mg/kgPart 2-0.7 mg/kgPart 2-0.7/0.4 mg/kg
Number of Participants With Hemoglobin > 10g/dL and Change From Baseline Hemoglobin ≥ 1g/dL22462
SecondaryLength of Time to Rescue Therapy

The length of time in days that participants who were rescued received treatment. When applicable, participants were rescued for anemia. During the rescue, participants discontinued sotatercept and were unblinded to the study treatment. Participants who were rescued continued in the treatment phase of 200 days and a follow-up phase of 112 days after the treatment phase. Rescue is defined as the need for a blood transfusion or Erythropoiesis-stimulating agent (ESA) therapy.

Time frame:
From first dose up to blood transfusion or ESA therapy, up to approximately 209 days
Reported as:
Mean · Days
Length of Time to Rescue Therapy
DaysPart 2- PlaceboPart 2-0.3 mg/kgPart 2-0.5 mg/kgPart 2-0.7 mg/kgPart 2-0.7/0.4 mg/kg
Length of Time to Rescue Therapy44.8 ± 43.9669.8 ± 59.1247.4 ± 32.86100.4 ± 55.73117.5 ± 73.37
SecondaryChange From Baseline in Hemoglobin Values

Dose Cycle 1 is defined as the first 28 days of treatment for Dose Groups 0.3 mg/kg, 0.5 mg/kg, and 0.7 mg/kg and the first 14 days of treatment for Dose Group 0.7/0.4 mg/kg. End of the Treatment Period is defined as the day before the follow-up phase started. Baseline is defined as hemoglobin measurements recorded on Day 1 of the first dose administered.

Time frame:
From first dose up to Day 225
Reported as:
Mean · g/L
Change From Baseline in Hemoglobin Values
g/LPart 2- PlaceboPart 2-0.3 mg/kgPart 2-0.5 mg/kgPart 2-0.7 mg/kgPart 2-0.7/0.4 mg/kg
End of Dose Cycle 1-3.3 ± 7.57-6.9 ± 6.94-2.9 ± 8.180.8 ± 5.851.0 ± 2.45
Peak Value During Dose Cycle 1-0.9 ± 7.085.2 ± 8.247.1 ± 3.988.4 ± 3.755.4 ± 4.10
End of Treatment Period12.5 ± 12.4212.8 ± 13.7515.3 ± 8.2215.0 ± 12.112.8 ± 6.91

Adverse events

Collected over Participants were assessed for all-cause mortality from their randomization to study completion, (up to approximately 66 months). SAEs and Other AEs were assessed from first dose up to 115 days post last dose (up to 340 days).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1 - Placebo0/1 (0%)0/1 (0%)1/1 (100%)
Part 1 - ACE-011 0.1 mg/kg1/6 (16.7%)2/6 (33.3%)6/6 (100%)
Part 2 - Placebo2/11 (18.2%)3/11 (27.3%)6/11 (54.5%)
Part 2 - 0.3 mg/kg0/9 (0%)4/9 (44.4%)8/9 (88.9%)
Part 2 - 0.5 mg/kg0/8 (0%)0/8 (0%)6/8 (75%)
Part 2 - 0.7 mg/kg0/9 (0%)5/9 (55.6%)8/9 (88.9%)
Part 2 - 0.7/0.4 mg/kg0/6 (0%)1/6 (16.7%)4/6 (66.7%)
Most frequent serious events
Showing 10 of 34
Most frequent serious events
EventPart 1 - PlaceboPart 1 - ACE-011 0.1 mg/kgPart 2 - PlaceboPart 2 - 0.3 mg/kgPart 2 - 0.5 mg/kgPart 2 - 0.7 mg/kgPart 2 - 0.7/0.4 mg/kg
ANGINA PECTORISCardiac disorders0/11/62/111/90/80/90/6
GASTROINTESTINAL HAEMORRHAGEGastrointestinal disorders0/10/60/110/90/80/91/6
CARDIAC FAILURE CONGESTIVECardiac disorders0/11/60/110/90/80/90/6
FLUID OVERLOADMetabolism and nutrition disorders0/11/60/110/90/80/90/6
RENAL FAILURE CHRONICRenal and urinary disorders0/11/60/110/90/80/90/6
ANAEMIABlood and lymphatic system disorders0/10/60/111/90/80/90/6
ACUTE MYOCARDIAL INFARCTIONCardiac disorders0/10/60/110/90/81/90/6
ANGINA UNSTABLECardiac disorders0/10/60/111/90/80/90/6
ATRIAL FIBRILLATIONCardiac disorders0/10/61/111/90/80/90/6
NAUSEAGastrointestinal disorders0/10/61/110/90/81/90/6
Most frequent other events
Showing 10 of 105
Most frequent other events
EventPart 1 - PlaceboPart 1 - ACE-011 0.1 mg/kgPart 2 - PlaceboPart 2 - 0.3 mg/kgPart 2 - 0.5 mg/kgPart 2 - 0.7 mg/kgPart 2 - 0.7/0.4 mg/kg
HYPOGLYCAEMIAMetabolism and nutrition disorders1/10/60/110/90/81/90/6
NAUSEAGastrointestinal disorders0/10/61/111/91/84/90/6
HYPERTENSIONVascular disorders0/10/61/113/90/84/90/6
FATIGUEGeneral disorders0/11/62/112/90/81/92/6
ARTERIOVENOUS FISTULA SITE COMPLICATIONInjury, poisoning and procedural complications0/12/61/110/91/80/90/6
CONSTIPATIONGastrointestinal disorders0/10/61/112/90/80/90/6
PAINGeneral disorders0/10/61/112/90/80/90/6
BLOOD PHOSPHORUS INCREASEDInvestigations0/10/60/110/90/82/90/6
DIZZINESSNervous system disorders0/10/60/110/90/82/90/6
HYPOTENSIONVascular disorders0/10/62/110/90/81/90/6

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Part 1-PlaceboPart 1-ACE-011 0.1 mg/kgPart 2- PlaceboPart 2-0.3 mg/kgPart 2-0.5 mg/kgPart 2-0.7 mg/kgPart 2-0.7/0.4 mg/kgTotal
<=18 years00000000
Between 18 and 65 years159765437
>=65 years012224213
Sex: Female, Male
Sex: Female, Male(Participants)Part 1-PlaceboPart 1-ACE-011 0.1 mg/kgPart 2- PlaceboPart 2-0.3 mg/kgPart 2-0.5 mg/kgPart 2-0.7 mg/kgPart 2-0.7/0.4 mg/kgTotal
Female114617121
Male057372529
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part 1-PlaceboPart 1-ACE-011 0.1 mg/kgPart 2- PlaceboPart 2-0.3 mg/kgPart 2-0.5 mg/kgPart 2-0.7 mg/kgPart 2-0.7/0.4 mg/kgTotal
Hispanic or Latino011242111
Not Hispanic or Latino1510747539
Unknown or Not Reported00000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part 1-PlaceboPart 1-ACE-011 0.1 mg/kgPart 2- PlaceboPart 2-0.3 mg/kgPart 2-0.5 mg/kgPart 2-0.7 mg/kgPart 2-0.7/0.4 mg/kgTotal
American Indian or Alaska Native00000000
Asian00200013
Native Hawaiian or Other Pacific Islander00000101
Black or African American036641424
White133347122
More than one race00000000
Unknown or Not Reported00000000
08

Study locations

24 sites
  • North American Research Institute
    Azusa, California 91702-3439, United States
  • West Glendale Dialysis
    Glendale, California 91205, United States
  • California Institute of Renal Research
    La Mesa, California 91942, United States
  • Academic Medical Center
    Los Angeles, California 90022, United States
  • Academic Medical Research Institute
    Los Angeles, California 90022, United States
  • Nephrology Specialist Medical Group
    Orange, California 92868, United States
  • Pines Clinical Research Inc.
    Pembroke Pines, Florida 33028, United States
  • University of Kentucky
    Lexington, Kentucky 40536, United States
  • Fresenius Medical Care North America MI
    Kalamazoo, Michigan 49007, United States
  • DaVita Clinical Research
    Minneapolis, Minnesota 55404, United States
  • Nephrology and Hypertension Associates, LTD
    Tupelo, Mississippi 38801, United States
  • St. Louis University Medical Center
    Saint Louis, Missouri 63110, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • Kidney Specialists of Southen Nevada
    Las Vegas, Nevada 89106, United States
  • Brookview Hill Research Associates, LLC
    Winston-Salem, North Carolina 27103, United States
  • MetroHealth Medical Systems
    Cleveland, Ohio 44109, United States
  • Northeast Clinical Research Center
    Bethlehem, Pennsylvania 18017, United States
  • Nephrology Associates, PC
    Nashville, Tennessee 37205, United States
  • Corva Kidney Center Webster
    Houston, Texas 77003, United States
  • Beechnut Dialysis Center
    Houston, Texas 77036, United States
  • Miracle Medical Clinic
    Houston, Texas 77055, United States
  • Gessner Dialysis Center
    Houston, Texas 77074, United States
  • Tyler Nephrology Associates, PC
    Tyler, Texas 75702, United States
  • University of Virginia at University Ave.
    Charlottesville, Virginia 22908, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2010 to primary completion in Mar 2016, 68 months.

Results were first posted in Mar 2024, 7 years 11 months after primary completion. A results delay was requested in Mar 2017.

Of 58 industry-sponsored phase 2 interventional studies under Anemia, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 40. This study's 68 months is above that.

Counting every sponsor, half of 88 studies reached it within 28 months; a quarter within 16 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2010
First posted
Jun 17, 2010
StartActual
Jun 30, 2010
Primary completionActual
Mar 7, 2016
CompletionActual
Mar 7, 2016
Results delay requested
Mar 7, 2017
Results first posted
Mar 1, 2024
Last update
Mar 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01146574
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Jun 17, 2010
Start date
Jun 30, 2010
Primary completion
Mar 7, 2016
Completion
Mar 7, 2016
Results posted
Mar 1, 2024
Last update
Mar 1, 2024

Study contacts

William T Smith, MD
study director · Celgene Corporation

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sotatercept

Start the discussion